Table 2 Pathological results and treatments for patients with uterine sarcoma
parameters | AS N=15 | ULMS N=63 | LG-ESS N=56 | HG-ESS N=16 | UUS N=5 | Total N=155 |
|---|---|---|---|---|---|---|
Surgical procedures | ||||||
Myomectomy | 1(6.67) | 4(6.35) | 1(1.79) | 0(0) | 0(0) | 6(3.87) |
TH | 0(0) | 10(15.87) | 9(16.07) | 0(0) | 0(0) | 19(12.26) |
H+USO | 0(0) | 0(0) | 0(0) | 1(6.25) | 0(0) | 1(0.65) |
H+BSO | 5(33.33) | 32(50.79) | 16(28.57) | 6(37.50) | 1(20.00) | 60(38.71) |
H+BSO+PLND | 8(53.33) | 16(25.40) | 27(48.21) | 9(56.25) | 4(80.00) | 64(41.29) |
H+USO+ PLND | 1(6.67) | 1(1.59) | 3(5.36) | 0(0) | 0(0) | 5(3.23) |
Mode of initial surgery | ||||||
Laparoscopy | 4(26.67) | 32(50.79) | 29(51.79) | 5(31.25) | 1(20.00) | 71(45.81) |
Laparotomy | 11(73.33) | 31(49.21) | 27(48.21) | 11(68.75) | 4(80.00) | 84(54.19) |
frozen section | ||||||
Malignant | 6/9(66.67) | 24/51(47.06) | 19/40(47.50) | 9/10(90.00) | 5/5(100) | 63/115(54.78) |
Malignant suspected | 1/9(11.11) | 20/51(39.22) | 7/40(17.50) | 1/10(10.00) | 0/5(0) | 29/115(25.22) |
Begin | 2/9(22.22) | 7/51(13.72) | 14/40(35.00) | 0/10(0) | 0/5(0) | 23/115(14.84) |
FIGOa | ||||||
I | 11(73.33) | 55(87.30) | 47(83.93) | 13(81.25) | 4(80.00) | 130(83.87) |
II | 1(6.67) | 4(6.35) | 5(8.93) | 1(6.25) | 1(20.00) | 12(7.74) |
III | 0(0) | 3(4.76) | 2(3.57) | 0(0) | 0(0) | 5(3.22) |
IV | 3(20.00) | 1(1.59) | 2(3.57) | 2(12.50) | 0(0) | 8(5.16) |
Adjuvant treatment | ||||||
chemotherapy | 5(33.33) | 33(52.38) | 13(23.21) | 10(62.50) | 3(60.00) | 64(41.29) |
radiotherapy | 0(0) | 1(1.59) | 0(0) | 0(0) | 0(0) | 1(0.65) |
Both | 0(0) | 1 (1.59) | 0(0) | 1(6.25) | 0(0) | 2(1.29) |
None | 10(66.67) | 28(44.44) | 43(76.79) | 5(31.25) | 2(40.00) | 88(56.77) |